Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDNA55 in Recurrent Glioblastoma
NCT02858895Phase 2Completed
- Sponsor
- Medicenna Therapeutics
- Start
- Apr 2017
- Primary completion
- Sep 2019
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of interleukin-4 pe38kdel in glioblastoma (GBM), sponsored by Medicenna Therapeutics. Started Apr 2017; status: completed.
02
Drugs
interleukin-4 pe38kdel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02858895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858895.